================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: April 1, 2004
QLT Inc.
--------------------------------------------------------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ ----------------------- -------------------
(Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
--------------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
================================================================================
ITEM 5. OTHER EVENTS
On April 1, 2004, QLT Inc. announced that effective April 1, 2004,
the Centers for Medicare and Medicaid Services will implement its
decision to provide coverage for ocular photodynamic therapy with
Visudyne(R) (verteporfin) to patients with age-related macular
degeneration who have occult and minimally classic lesions that are
four disc areas or less in size and show evidence of recent disease
progression.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------- -----------
99.1 Press release dated April 1, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
----------------
(Registrant)
Date April 1, 2004 /s/ Paul J. Hastings
-------------------------- -------------------------------
(Signature)
President and Chief
Executive Officer